On the stock market since 2025, it operates in the world of health and science. It has 2 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
The stock trades 58% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 12 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $6.0M against $0 in annual sales.
This stock swings about 3.7 times as much as the market average. Big rallies — and big drops — can both happen fast.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, APUS sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: APUS is a high-risk stock — not yet profitable, and its future rides on its product catching on.